477 related articles for article (PubMed ID: 18996003)
1. Management and outcome of stage 3 neuroblastoma.
Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
3. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
[TBL] [Abstract][Full Text] [Related]
4. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.
Kushner BH; Modak S; Kramer K; LaQuaglia MP; Yataghene K; Basu EM; Roberts SS; Cheung NK
Cancer; 2014 Jul; 120(13):2050-9. PubMed ID: 24691684
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
6. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
[TBL] [Abstract][Full Text] [Related]
7. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
8. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
9. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status.
Simon T; Spitz R; Faldum A; Hero B; Berthold F
J Pediatr Hematol Oncol; 2004 Dec; 26(12):791-6. PubMed ID: 15591897
[TBL] [Abstract][Full Text] [Related]
10. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
11. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
12. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
[TBL] [Abstract][Full Text] [Related]
13. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
14. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
[TBL] [Abstract][Full Text] [Related]
15. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
[TBL] [Abstract][Full Text] [Related]
16. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA; Rubie H; Castel V; Beiske K; Holmes K; Gambini C; Casale F; Munzer C; Erminio G; Parodi S; Navarro S; Marquez C; Peuchmaur M; Cullinane C; Brock P; Valteau-Couanet D; Garaventa A; Haupt R
Eur J Cancer; 2013 Nov; 49(17):3671-9. PubMed ID: 23907002
[TBL] [Abstract][Full Text] [Related]
18. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment.
Boztug K; Kiely E; Roebuck DJ; Gaze M; Begent J; Brock P; Michalski A
Pediatr Blood Cancer; 2006 Feb; 46(2):253-7. PubMed ID: 15926157
[TBL] [Abstract][Full Text] [Related]
20. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]